This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

TREMFYA - Latex Content

Last Updated: 10/10/2024

LATEX CONTENT

  • Please refer to the local labeling for relevant information regarding approved dosage forms and strengths of TREMFYA.
  • The immediate containers or excipients of TREMFYA formulations below are not made with natural rubber latex.1
    • TREMFYA 100 mg/mL in a single-dose One-Press patient-controlled injector.
    • TREMFYA 200 mg/2 mL in a single-dose prefilled pen (TREMFYA PEN).
    • TREMFYA 100 mg/mL in a single-dose prefilled syringe.
    • TREMFYA 200 mg/2 mL in a single-dose prefilled syringe.
    • TREMFYA 200 mg/20 mL (10 mg/mL) solution in a single-dose vial.

However, we cannot guarantee that the excipients do not come in contact with latex during the manufacturing or packaging process (eg, latex gloves).1

 

References

1 Data on File. Technical document - patient safety and compliance information of TREMFYA (guselkumab) 100 mg/mL and guselkumab Crohn’s disease PFS 2 mL (200 mg) and 200 mg FVP v6. Janssen Material Sciences; 2024.